BG61250B1 - Фармацевтичен състав,предназначен за въздействиевърху ретикуло- ендотелната система,метод за получаване и приложението му - Google Patents

Фармацевтичен състав,предназначен за въздействиевърху ретикуло- ендотелната система,метод за получаване и приложението му Download PDF

Info

Publication number
BG61250B1
BG61250B1 BG96686A BG9668692A BG61250B1 BG 61250 B1 BG61250 B1 BG 61250B1 BG 96686 A BG96686 A BG 96686A BG 9668692 A BG9668692 A BG 9668692A BG 61250 B1 BG61250 B1 BG 61250B1
Authority
BG
Bulgaria
Prior art keywords
compound
composition according
acid
composition
amount
Prior art date
Application number
BG96686A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG96686A (bg
Inventor
Jozsef Beres
Jun. Jozsef Beres
Original Assignee
Beres Export-Import Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beres Export-Import Rt. filed Critical Beres Export-Import Rt.
Publication of BG96686A publication Critical patent/BG96686A/bg
Publication of BG61250B1 publication Critical patent/BG61250B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Electrotherapy Devices (AREA)
  • Circuits Of Receivers In General (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
BG96686A 1991-07-24 1992-07-24 Фармацевтичен състав,предназначен за въздействиевърху ретикуло- ендотелната система,метод за получаване и приложението му BG61250B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU912492A HU207799B (en) 1991-07-24 1991-07-24 Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis

Publications (2)

Publication Number Publication Date
BG96686A BG96686A (bg) 1993-12-24
BG61250B1 true BG61250B1 (bg) 1997-04-30

Family

ID=10959658

Family Applications (1)

Application Number Title Priority Date Filing Date
BG96686A BG61250B1 (bg) 1991-07-24 1992-07-24 Фармацевтичен състав,предназначен за въздействиевърху ретикуло- ендотелната система,метод за получаване и приложението му

Country Status (18)

Country Link
US (2) US5312629A (de)
EP (1) EP0524633B1 (de)
JP (1) JP2673852B2 (de)
KR (1) KR100234855B1 (de)
AT (1) ATE178213T1 (de)
BG (1) BG61250B1 (de)
CA (1) CA2074639C (de)
CZ (1) CZ281672B6 (de)
DE (1) DE69228777T2 (de)
FI (1) FI923364A7 (de)
HR (1) HRP920192B1 (de)
HU (1) HU207799B (de)
PL (1) PL169684B1 (de)
RO (1) RO109505B1 (de)
RU (1) RU2093160C1 (de)
SI (1) SI9200155A (de)
SK (1) SK278944B6 (de)
YU (1) YU48243B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871779A (en) * 1994-01-18 1999-02-16 Mount Sinai Hospital Corporation Treatment of arthropathies with vanadate compounds or analogues thereof
US5843481A (en) * 1994-01-18 1998-12-01 Mount Sinai Hospital Corporation Treatment of proliferative disorders, metastasaes, and drug resistant tumors with vanadate compounds and derivatives or analogues thereof
GB9416768D0 (en) * 1994-08-18 1994-10-12 Nycomed Innovation Ab Compositions
WO1996005867A2 (en) * 1994-08-18 1996-02-29 Nycomed Imaging A/S Compositions
GB9416767D0 (en) * 1994-08-18 1994-10-12 Nycomed Innovation Ab Compositions
US5863519A (en) * 1994-08-18 1999-01-26 Nycomed Imaging As Composition and method of MRI using both a positive and a negative contrast agent
FR2740342B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, de manganese, de lithium, d'etain, de zinc ou d'yttrium, de cobalt, de baryum, de strontium dans des compositions pharmaceutiques
RU2146146C1 (ru) * 1999-05-05 2000-03-10 Дубинина Лариса Васильевна Репаративно-регенеративный препарат, способ его изготовления и лечебного использования по л.в.дубининой
US20030170318A1 (en) * 2000-09-29 2003-09-11 Steiner Gregory Gene Fluoride compositions and uses thereof
US6638431B2 (en) * 2001-05-03 2003-10-28 Mainstream Engineering Corporation Formulation and method for treating wetted surface elements in climate control systems
KR20050018250A (ko) * 2003-08-14 2005-02-23 한영주 복합생약 조성물을 함유하는 항암활성을 갖는 조성물
KR100889994B1 (ko) * 2003-08-14 2009-03-24 한영미 녹반을 함유하는 항암활성을 갖는 조성물
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
WO2006130027A1 (en) * 2005-05-31 2006-12-07 Santos Ma Joyce Bedelia B Aqueous oral liquid vitamin supplements containing stabilized vitamin c and metal ions
WO2006130839A1 (en) * 2005-06-02 2006-12-07 U.S. Borax Inc. Prevention and treatment of osteochondrosis in animals and humans
RU2009125565A (ru) * 2006-12-06 2011-01-20 Ю. Эс. Боракс Инк. (Us) Композиции корма для животных
EP1949894B1 (de) * 2007-01-25 2016-06-29 Roche Diagnostics GmbH Verstärkung von vanadiumhaltigen Phosphatasehemmern mit Polyole
US8008035B2 (en) 2007-01-25 2011-08-30 Roche Diagnostics Operations, Inc. Enhancement of vanadium-containing phosphatase inhibitors
US10634385B2 (en) 2009-09-03 2020-04-28 Ademco Inc. Heat balancing system
WO2013167298A1 (en) 2012-05-11 2013-11-14 Kael-Gemvax Co., Ltd. Anti-inflammatory peptides and composition comprising the same
ES2981865T3 (es) 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
RU2677277C2 (ru) 2013-06-07 2019-01-16 Джемвакс Энд Каэл Ко., Лтд. Биологические маркеры, которые могут быть использованы в иммунотерапии рака
JP6495899B2 (ja) 2013-06-21 2019-04-03 ジェムバックス アンド カエル カンパニー，リミティド ホルモン分泌調節剤、及びそれを含む組成物
KR102314231B1 (ko) 2013-12-17 2021-10-19 주식회사 젬백스앤카엘 전립선 암 치료용 조성물
WO2015126265A1 (en) * 2014-02-18 2015-08-27 Santos Joyce Bedelia B Oral liquid vitamin supplements containing zinc and stabilized vitamin c with reduced astringency
WO2015156649A1 (ko) 2014-04-11 2015-10-15 주식회사 젬백스앤카엘 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
JP6466971B2 (ja) 2014-04-30 2019-02-06 ジェムバックス アンド カエル カンパニー，リミティド 臓器、組織又は細胞移植用組成物、キット及び移植方法
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
KR102636129B1 (ko) 2015-02-27 2024-02-14 주식회사 젬백스앤카엘 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물
KR102638286B1 (ko) 2015-07-02 2024-02-20 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
US10898540B2 (en) 2016-04-07 2021-01-26 Gem Vax & KAEL Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
CN114177196B (zh) * 2020-09-14 2025-12-05 深圳市方升泰医药科技有限公司 钒化合物用于治疗疼痛的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2022998B (en) * 1978-06-14 1982-09-08 Beres J Phermaceutical composition for the treatment of neoplasticand other diseases
JPS554348A (en) * 1978-06-26 1980-01-12 Peresu Yozefu Drug composition for treating variety of illness by influence to reticuloendotherial tissue and method of treating maligmant tumor with said composition in treating human

Also Published As

Publication number Publication date
EP0524633A3 (en) 1993-07-28
BG96686A (bg) 1993-12-24
JP2673852B2 (ja) 1997-11-05
FI923364A0 (fi) 1992-07-24
ATE178213T1 (de) 1999-04-15
YU81092A (sr) 1996-01-09
CA2074639A1 (en) 1993-01-25
CZ232692A3 (en) 1993-02-17
RU2093160C1 (ru) 1997-10-20
US5312629A (en) 1994-05-17
YU48243B (sh) 1997-08-22
PL169684B1 (pl) 1996-08-30
CZ281672B6 (cs) 1996-12-11
HU207799B (en) 1993-06-28
US5405620A (en) 1995-04-11
RO109505B1 (ro) 1995-03-30
CA2074639C (en) 1996-01-09
EP0524633A2 (de) 1993-01-27
HUT61475A (en) 1993-01-28
KR100234855B1 (ko) 1999-12-15
PL295352A1 (en) 1993-02-22
SK278944B6 (sk) 1998-05-06
HRP920192A2 (hr) 1994-04-30
HRP920192B1 (en) 2000-06-30
FI923364A7 (fi) 1993-01-25
SI9200155A (en) 1993-03-31
KR930001915A (ko) 1993-02-22
JPH06227992A (ja) 1994-08-16
DE69228777T2 (de) 1999-10-21
HU912492D0 (en) 1991-12-30
EP0524633B1 (de) 1999-03-31
SK232692A3 (en) 1995-06-07
DE69228777D1 (de) 1999-05-06

Similar Documents

Publication Publication Date Title
BG61250B1 (bg) Фармацевтичен състав,предназначен за въздействиевърху ретикуло- ендотелната система,метод за получаване и приложението му
BAUER et al. Vitamin D intoxication with metastatic calcification
US7375243B2 (en) Method for preparation of amino acid chelate
McCRORY et al. Renal excretion of inorganic phosphate in newborn infants
Cadman et al. Gastro‐esophageal Reflux in Severely Retarded Children
Balucani et al. Podophyllum resin poisoning with complete recovery
Corner Hypertrophic pyloric stenosis in infancy treated with methyl scopolamine nitrate
CN106858610B (zh) 一种氨基酸螯合钙的制备方法及包括该螯合钙的补钙制剂
US7423063B2 (en) Calcium salts with cytotoxic activity
CN101264105A (zh) 羔羊胃提取物维b12制剂组方
Pretorius et al. The effect of various skimmed milk formulae on the diarrhoea, nitrogen retention and initiation of cure in kwashiorkor
HANISSIAN et al. Arthritis of sickle cell anemia
CN107412261A (zh) 具有修复代谢功能的清糖口服液及其制备方法
Sjoberg et al. Nutritional studies in the dumping syndrome: III. Retention of orally administered47 calcium in patients after gastrectomy
THERAP section of Eberapeuticz anb Pbarmacoloop.
CN109674799B (zh) 桦木酸在机体排铅以及制备排铅食品、保健品和药物中的应用
McChesney et al. Some applications of ion exchange resins to medical problems
CH641045A5 (en) Pharmaceutical preparation, in particular for the cure and prevention of neoplastic diseases
McCabe Ileocecal tuberculosis with target cell anemia
Miller Pituitary hypothyroidism with impaired renal function
Lucas et al. The absorption and utilization of iron salts
Freiman Protein energy malnutrition and its treatment
Davies et al. Dehydration and fat babies
Fortescue-Brickdale A practical guide to the newer remedies
Kauvar COMPARATIVE STUDY WITH A NEW ANTACID TABLET.